drugset / Trial / NCT01118598
Effect of Nicotinic Acid on Cardiovascular Risks Indices in Polycystic Ovary Syndrome
Phase 4
Completed
34 enrolled
Hull University Teaching Hospitals NHS Trust
Merck Sharp & Dohme LLC · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
Niacin will improve postprandial hyperlipidaemia and cardiovascular risks indices via its lipid lowering as well as via pleiotropic effects in patients with polycystic ovary syndrome (PCOS).
Timeline
- Start
- 2010-06
- Primary completion
- 2012-05
- Completion
- 2012-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Niacin | Small molecule | 2000 mg | — |
| Comparator | laropiprant | Small molecule | 40 mg | — |